Jesus Maria Ontoria

Jesus Maria Ontoria

Auto-generated profile, based on publicly available information

Jesus Maria Ontoria

Department of Drug Discovery, IRBM S.p.A., Pomezia, Italy.

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2009 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
JHJose Ignacio Martin Hernando
Jose Ignacio Martin Hernando
JOJesus Maria Ontoria
Jesus Maria Ontoria
SMSavina Malancona
Savina Malancona
BABarbara Attenni
Barbara Attenni
FFFabrizio Fiore
Fabrizio Fiore
FNFrank Narjes
Frank Narjes

3 April 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JOJesus M. Ontoria
Jesus M. Ontoria
IBIlaria Biancofiore
Ilaria Biancofiore
PFPaola Fezzardi
Paola Fezzardi
FFFederica Ferrigno
Federica Ferrigno
ETEsther Torrente
Esther Torrente
SHSteven Harper
Steven Harper

23 January 2022 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SCstefania colarusso
stefania colarusso
FFFederica Ferrigno
Federica Ferrigno
SPSimona Ponzi
Simona Ponzi
FPFrancesca Pavone
Francesca Pavone
ICImmacolata Conte
Immacolata Conte
JOJesus M. Ontoria
Jesus M. Ontoria

1 December 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
FFFederica Ferrigno
Federica Ferrigno
IBIlaria Biancofiore
Ilaria Biancofiore
SMSavina Malancona
Savina Malancona
SPSimona Ponzi
Simona Ponzi
GPGiacomo Paonessa
Giacomo Paonessa
JOJesus M. Ontoria
Jesus M. Ontoria

10 February 2026 in Nature Communications
Verified
Journal Article
Open access
JOJesus M. Ontoria
Jesus M. Ontoria
ETEsther Torrente
Esther Torrente
AMAntonino Missineo
Antonino Missineo
CACristina Alli
Cristina Alli
RGRita Graziani
Rita Graziani
GPGiacomo Paonessa
Giacomo Paonessa
The mosquito-transmitted Zika virus (ZIKV) poses a global health threat, with no approved antiviral drugs or vaccines currently available. Here, we report the discovery of a series of ZIKV NS3 protease inhibitors identified through phenotypic high-throughput screening (HTS) using a ZIKV replicon-based cellular assay, and the subsequent selection of resistant mutants. These inhibitors, characterized by the presence of an N -acylsydnone imine group, bind to a previously undescribed allosteric pocket of the protease, locking the enzyme into a catalytically inactive conformation. We describe the characterization of IRBM-Z-1, our initial allosteric hit and IRBM-Z-2, a potent inhibitor of ZIKV infectivity and other orthoflavivirus proteases with a favourable in vitro and in vivo ADME profile, resulting in oral efficacy against ZIKV infection in mouse models, with potential as a prophylactic agent for human use.